Monoclonal antibodies to the human LDL receptor, their production and use

• US 6,849,720 B2
• Filed: 03/08/2001
• Issued: 02/01/2005
• Est. Priority Date: 03/13/2000
• Status: Expired due to Fees

• Current Assignee: Merck Serono SA (Merck & Co., Inc.)
• Original Assignee: Applied Research Systems ARS Holding NV (Merck & Co., Inc.)
• Inventors: Belzer, Ilana, Smolarsky, Moshe, Antonetti, Francesco, Yonah, Nachum, Suissa, Dany, Dreano, Michel
• Primary Examiner(s): Chin, Christopher L.
• Assistant Examiner(s): GRUN, JAMES LESLIE
• Application Number:
  US10/221,679
• Publication Number:
  US 20030186343A1
• Time in Patent Office: 1,426 Days
• Field of Search: 435/5, 435/7.21, 435/7.94, 435/70.21, 435/452, 435/328, 435/332, 435/334, 436/518, 436/548, 436/820, 424/143.1, 424/172.1, 514/2, 530/388.22, 530/387.2, 530/387.3, 530/413
• US Class Current: 530/388.22
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: Y10S 436/82 Hepatitis associated antigens and antibodies

Abstract

There are provided monoclonal antibodies to the LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection.

Claims

1. A monoclonal antibody expressed by hybridoma clone 12.6 deposited at the CNCM under No.1-2390.

11. A method for purifying human low-density receptor (LDLR) which comprises contacting a material containing crude human LDLR with the monoclonal antibody according to any one of claims 1-5 to affinity purify human LDLR.

12. A method for neutralizing an antiviral biological activity of recombinant human soluble low-density lipoprotein receptor (r-hsLDLR) comprising contacting r-hsLDLR with the monoclonal antibody of claim 1 or 5 to neutralize an antiviral biological activity of r-hsLDLR.

13. A method for inhibiting replication of hepatitis C virus, comprising contacting cells with the monoclonal antibody of claim 1, 2 or 3 prior to infection by hepatitis C virus to inhibit replication of hepatitis C in the cells.

2. A monoclonal expressed by hybridoma clone 28 deposited at the CNCM under No. I-2391.

3. A monoclonal antibody expressed by hybridoma clone 29.8 deposited at the CNCM under No. I-2392.

4. A monoclonal antibody expressed by hybridoma clone 30 deposited at the CNCM under No. I-2393.

5. A monoclonal antibody expressed by hybridoma clone 50.30 deposited at the CNCM under No. I-2394.

6. A hybridoma clone 12.6 deposited at the CNCM under No.1-2390.

7. A hybridoma clone 28 deposited at the CNCM under No.1-2391.

8. A hybridoma clone 29.8 deposited at the CNCM under No.1-2392.

9. A hybridoma clone 30 deposited at the CNCM under No.1-2393.

10. A hybridoma clone 50.30 deposited at the CNCM under No. I-2394.